Welcome to the e-CCO Library!

DOP71: Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Li*1, J. R. Friedman1, C. Marano1, H. Zhang1, F. Yang1, B. G. Feagan2, L. Peyrin-Biroulet3, G. De Hertogh4

Created: Friday, 22 February 2019, 9:41 AM
DOP71: Fungal and bacterial gut microbiota in paediatric onset Inflammatory Bowel Disease introduced to infliximab
Year: 2021
Source: ECCO'21 Virtual
Authors: Ventin-Holmberg, R.(1);Höyhtyä, M.(2);Saqib, S.(3);Korpela, K.(3);Nikkonen, A.(4);Salonen, A.(3);de Vos, W.M.(5);Kolho, K.L.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP71: Low occurrence of colectomy with long-term (up to 4 years) golimumab treatment in patients with moderate-to-severe active Ulcerative Colitis: Data from the PURSUIT maintenance and long-term extension studies
Year: 2022
Source: ECCO'22
Authors: Weinstein, C.L.(1);Meehan, A.G.(2);Lin, J.(3);Govoni, M.(4);Qureshi, Z.P.(5);
Created: Friday, 11 February 2022, 3:52 PM
DOP71: TREM1, OSM and a co-expressed transcriptional module are core components of the molecular resistome to anti-cytokine therapy in Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Saifuddin, A.(1)*;Madgwick, M.(2);Cozzetto, D.(1);Pavlidis, P.(3);Verstockt, B.(4,5);Hart, A.(1,6);Korcsmaros, T.(1);Powell, N.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Danese1, M. Klopocka2, E.J. Scherl3, J. Romatowski4, J.R. Allegretti5, E. Peeva6, M.S. Vincent6, U. Schoenbeck7, L. Xi6, Z. Ye6, M. Hassan-Zahraee6, N. Rath8, G. Li8, S. Neelakantan6, C. Banfield6, C. Lepsy9, D. Chandra6, K.E. Hung6

Created: Thursday, 30 January 2020, 10:12 AM
DOP72: HLA-DQA1*05 associates with immunogenicity and loss of response to anti-TNF therapy in the IBD population: A meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bergstein, S.(1)*;Spencer, E.A.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP72: Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasia
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. de Jong*1, H. Kanne1, L. Nissen2, I. Nagtegaal3, J. Drenth1, L. Derikx1,2, F. Hoentjen1

Created: Friday, 22 February 2019, 9:41 AM
DOP72: Perianal Crohn’s Disease in the biologic era: A population-based cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Jenkinson, P.(1);Plevris, N.(1);Lyons, M.(1);Siakavellas, S.(1);Arnott, I.(1);Jones, G.R.(1);Watson, A.(2);Lees, C.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP72: The association of anti-tumor necrosis factor and thiopurine therapy with the risk of lymphoma among Inflammatory Bowel Disease patients: A nation-wide study from the epi-IIRN
Year: 2022
Source: ECCO'22
Authors: WatermanM.D, M.(1);Lavi, I.(2);Harel, S.(3);Focht, G.(4);Loewenberg Weisband, J.(5);Greenfeld, S.(6);Kariv, R.(6);Ledderman, N.(7);Matz, E.(8);Keinan-Boker, L.(9);Eizenstein, S.(10);Dotan, I.(11);Turner, D.(4);Levi, Z.(12);
Created: Friday, 11 February 2022, 3:52 PM
DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B.E. Sands1, A.C. Moss2, A. Armuzzi3, J.K. Marshall4, J.O. Lindsay5, W.J. Sandborn6, S. Danese7, M. Zeroncio8, I. Modesto9, L. Salese10, N. Lawendy10, H. Zhang10, C. Su10

Created: Thursday, 30 January 2020, 10:12 AM
DOP73: A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn’s Disease and Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Peyrin-Biroulet, L.(1);Arkkila, P.(2);Armuzzi, A.(3);Atreya, R.(4);Danese, S.(5);Ferrante, M.(6);Guardiola, J.(7);Jahnsen, J.(8);Louis, E.(9);Lukáš, M.(10);Reinisch, W.(11);Roblin, X.(12);Smith, P.J.(13);Kwon, T.S.(14);Kim, J.Y.(14);Yoon, S.W.(15);Kim, D.H.(15);
Created: Friday, 11 February 2022, 3:52 PM
DOP73: Antibiotic use differentially affects the risk of antidrug antibody formation during anti-TNFα therapy in Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Gorelik, Y.(1);Freilich, S.(2);Gerassy-Vainberg, S.(1);Blatt, A.(1);Pressman, S.(1);Focht, G.(3);Friss, C.(3);Loewenberg Weisband, Y.(4);Greenfeld, S.(5);Kariv, R.(5);Ledderman, N.(6);Iris, D.(7);Kashi, Y.(8);Turner, D.(3);Chowers, Y.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP73: Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wong, E.C.L.(1);Dulai, P.S.(2);Marshall, J.K.(1);Jairath, V.(3);Reinisch, W.(4);Narula, N.(1)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP73: Treatment of perianal fistulas in Crohn’s disease, seton vs. anti-TNF vs. surgical closure following anti-TNF (PISA): a randomised controlled trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Wasmann*1, E. J. de Groof2, M. Stellingwerf1, G. D'Haens3, C. Ponsioen3, K. Gecse3, M. Dijkgraaf4, W. Bemelman2, C. Buskens2

Created: Friday, 22 February 2019, 9:41 AM
DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

U. Kopylov1, J. Hanzel2, C. Liefferinckx3, D. De Marco4, N. Imperatore5, N. Plevris6, I. Baston-Rey7, R. Harris8, M. Truyens9, V. Domislovic10, S. Vavricka11, V. Biemans12,13, S. Myers14, S. Shaji14, S. Ben-Horin1, Y. González Lama15, C. Gilletta16, A. Bar-Gil Shitrit17, Z. Zelinkova18, R. Weishof19, D. Storan20, E. Zittan21, D. Franchimont3, A. Cremer3, W. Afif4, F. Castiglione5, C. Lees7, M. Barrero de Acosta7, T. Lobaton9, G. Doherty20, Z. Krznaric10, M. Pierik12, F. Hoentjen13, D. Drobne2

Created: Thursday, 30 January 2020, 10:12 AM
DOP74: Artificial Intelligence Quantifying Endoscopic Severity of Ulcerative Colitis in Gradation Scale
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Takabayashi, K.(1)*;Kobayashi, T.(2);Matsuoka, K.(3);G Levesque, B.(4);Kawamura, T.(5);Tanaka, K.(5);Kadota, T.(6);Bise, R.(6);Uchida, S.(6);Kanai, T.(7);Ogata, H.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP74: Comparative effectiveness of vedolizumab and ustekinumab in Crohn’s Disease patients who failed anti-TNF treatment: Interrogating 1019 patients from the UK IBD BioResource
Year: 2022
Source: ECCO'22
Authors: Desoki, R.(1,2);Balendran, K.(1);Kapizioni, C.(1);Shawky, R.(1);Parkes, M.(1);Raine, T.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP74: Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Biron*1, P. Seksik2, M. Nachury3, Y. Bouhnik4, A. Amiot5, S. Viennot6, M. Serrero7, M. Fumery8, M. Allez9, L. Siproudhis10, A. Buisson11, G. Pineton de Chambrun12, V. Abitbol13, S. Nancey14, L. Caillo15, L. Plastaras16, L. Armengol-Debeir17, E. Chanteloup18, M. Simon19, N. Dib20, S. Rajca21, M. Amil22, L. Peyrin-Biroulet23, L. Vuitton24

Created: Friday, 22 February 2019, 9:41 AM
DOP74: Initial Clearance of infliximab is a predictor for the time of formation of anti-drug antibodies
Year: 2021
Source: ECCO'21 Virtual
Authors: Kutschera, M.(1);Primas, C.(1);Reinisch, S.(1);Novacek, G.(1);Kim, S.H.(2);Lee, S.H.(2);Lee , J.H.(2);Reinisch, W.(1);Mould, D.R.(3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP75 Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D.T. Rubin1, M.C. Dubinsky2, J. Panés3, D.C. Wu4, N. Lawendy5, X. Guo5, C. Lai6, K. Kwok7, C. Su5, L. Salese5

Created: Thursday, 30 January 2020, 10:12 AM